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Primary graft dysfunction (PGD), a form of acute lung
injury occurring within 72 h following lung transplanta-
tion, is characterized by pulmonary edema and diffuse
alveolar damage. We hypothesized that higher concen-
trations of intercellular adhesion molecule-1 (ICAM-1)
and von Willebrand factor (vWF) would be associated
with the occurrence of PGD. A total of 128 lung trans-
plant recipients among 7 lung transplant centers were
enrolled in a multicenter, prospective, cohort study.
Blood specimens were collected preoperatively and
at 6, 24, 48 and 72 h following lung transplantation.
The primary outcome was Grade 3 PGD at 72 h af-
ter transplant. Logistic regression and generalized es-
timating equations (GEE) were used to analyze plasma
ICAM-1 and vWF. At each postoperative timepoint,
mean plasma ICAM-1 concentrations were higher for
patients with PGD versus no PGD. The GEE contrast es-
timate for the association of plasma ICAM-1 with PGD
was 107.5 ng/mL (95% CI 38.7, 176.3), p = 0.002. In the
multivariate analyses, this finding was independent of
all clinical variables except pulmonary artery pressures
prior to transplant. There was no association between
plasma vWF levels and PGD. We conclude that higher
levels of plasma ICAM-1 are associated with PGD fol-
lowing lung transplantation.
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Introduction
Primary graft dysfunction (PGD) is a form of acute lung
injury (ALI) occurring within 72 h following lung transplan-
tation. Characterized by noncardiogenic pulmonary edema
and diffuse alveolar damage, PGD occurs in 10–25% of
lung transplant recipients and dramatically reduces short-
term survival (1–4). A diagnosis of pulmonary arterial hyper-
tension and high preoperative pulmonary artery pressures
both increase the risk of PGD; however, the exact causes
of PGD are unknown (5–8).
ALI is characterized by increased circulating plasma indi-
cators of inflammation and endothelial dysfunction (9,10).
ICAM-1 is a low molecular weight adhesion molecule that
is highly expressed by Type-I pneumocytes, alveolar cap-
illary endothelium and neutrophils. In patients with ALI,
higher levels of plasma ICAM-1 were found to be asso-
ciated with increased mortality and prolonged mechanical
ventilation (9,10). The von Willebrand Factor is a large mul-
timeric glycoprotein synthesized by endothelial cells and
megakaryocytes. The vWF stabilizes Factor VIII and initi-
ates the platelet plug. Endothelial injury leads to elevated
vWF levels, whereas platelet-derived vWF does not sig-
nificantly contribute to circulating levels. Elevated plasma
levels of vWF are associated with worse outcomes in pa-
tients with pulmonary arterial hypertension, as well as pa-
tients with ALI (11–16).
We aimed to determine the association of postoperative
levels and dynamic changes of ICAM-1 and vWF with PGD
after lung transplantation. We hypothesized that higher
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plasma levels of ICAM-1 and vWF would be associated
with the occurrence of PGD following lung transplantation.
Materials and Methods
We performed a multicenter, prospective cohort study at seven lung trans-
plant centers in the United States. The Lung Transplant Outcomes Group
(LTOG) included the University of Pennsylvania, Vanderbilt University, Uni-
versity of Alabama at Birmingham, University of Michigan, Johns Hopkins
University, Stanford University and Columbia University. One hundred and
twenty-eight lung transplant recipients were enrolled between June 2003
and November 2004. Patients undergoing multi-organ transplantation were
excluded. Details of the study sample have been previously published (17).
The primary outcome was Grade 3 PGD (hereafter referred to as PGD),
defined as diffuse alveolar infiltrates in the lung allograft(s) on chest radio-
graphs with a PaO2/FiO2 less than 200 mmHg, graded at 72 h. Further
details of this definition have been previously published (2). Blood samples
were collected preoperatively (at the time of admission for transplantation),
and 6, 24, 48 and 72 hours following lung transplantation. Samples were
processed within 30 min and stored at −80◦C until analysis. Soluble ICAM-
1 was measured in plasma by ELISA (R & D Systems, Inc., Minneapolis,
MN) and expressed as ng/mL. The vWF in plasma was measured by ELISA
(Diagnostica Stago, Parsippany, NJ) and expressed as a percentage of a
normal pooled plasma control reference that has been assayed against a
secondary standard of the Fourth International Standard of vWF. All samples
were measured in duplicate. The coefficients of variation for ICAM-1 and
vWF were both 3%. To place the findings of our cohort study in context, we
also measured ICAM-1 levels in 10 normal, healthy controls, recruited from
Vanderbilt University. Plasma vWF levels have previously been reported by
our group (15).
Levels of ICAM-1 and vWF for patients with PGD were compared to patients
without PGD using the Student’s t-test or rank-sum tests as appropriate.
Spearman rank correlations were used to compare continuous measures.
Comparison of biomarkers by group variables (such as diagnosis category)
was performed by ANOVA and ANCOVA. Dynamic biomarker profiles were
plotted by PGD status and compared using generalized estimating equa-
tions (GEE), which are statistical models used to compare differences in
longitudinal continuous measures.
Multivariable logistic regression included plasma biomarkers (independent
variables), potential confounding variables, and PGD status (dependent vari-
able). Variables with a p-value <0.20 on bivariate analysis with PGD status
were considered potential confounders; such variables were included in
the model one at a time to avoid overfitting. In addition, we used logistic
regression to determine the association between biomarker level and mor-
tality at 30 days after transplantation. Statistical analyses were performed
using STATA version 9.2 (STATA data Corporation, College Station, TX) and
SAS version 9.1 (SAS Institute, Cary, NC).
Informed consent was obtained for enrollment prior to lung transplantation,
and the research protocol was approved by the Institutional Review Board
of each center.
Results
Baseline characteristics of the subjects enrolled in the co-
hort study are shown in Table 1 and have been previously
reported in part (17). Six subjects died within 30 days of
transplant. Twenty-six patients (20%, 95% CI 14%, 28%)
Table 1: Donor and recipient characteristics
No PGD PGD
Donor variables n = 102 n = 26 p-Value
Age (years) 30 (28,33) 32 (25,39) 0.54
Female gender 37% 43% 0.59
Race/ethnicity 0.28
Caucasian 66% 76%
African American 21% 5%
Hispanic 13% 14%
Other 1% 5%
Recipient and surgical variables
Age (years) 52 (49,55) 45 (39,53) 0.06
Female gender 47% 31% 0.11
Race/ethnicity 0.06
Caucasian 90% 81%


























40 (37,43) 61 (45,77) <0.001
Adapted in part from reference 17. Continuous variables are ex-
pressed as means with 95% confidence intervals and dichoto-
mous variables as column percentages.
met the criteria for PGD. Characteristics associated with a
higher risk of PGD included: recipient diagnosis of diffuse
parenchymal lung disease or pulmonary arterial hyperten-
sion, bilateral lung transplantation, use of cardiopulmonary
bypass and high pulmonary artery systolic pressure at in-
duction of anesthesia.
Plasma ICAM-1 levels were higher in PGD patients than in
others at every postoperative time point (p < 0.05 at 6 h, p
< 0.0001 at 24 h and p < 0.001 at 48 and 72 h) (Figure 1).
Preoperative plasma levels of ICAM-1 also were higher in
patients who went on to develop PGD, but this difference
did not reach statistical significance (p = 0.059). The con-
trast estimate derived from GEE was 107.5 ng/mL (p =
0.002 and 95% CI 39, 176) indicating that, on average, the
ICAM-1 level was over 100 ng/mL higher in PGD patients
compared to non-PGD patients over the 72-h postoperative
time course.
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trations over time for lung
transplant recipients with
and without primary graft
dysfunction (PGD). Data
are presented as mean ±
standard error. ∗p < 0.05,
∗∗p < 0.001 for PGD versus
no PGD.
We then tested the association of 24-h ICAM-1 levels with
the risk of PGD after adjustment for potential confounders
(Table 2). The increase in concentrations of ICAM-1 was
independent of clinical variables such as ischemic time,
transfusion, diagnosis category or use of cardiopulmonary
bypass or nitric oxide. However, inclusion of pulmonary
artery systolic pressure in the model attenuated the re-
lationship between ICAM-1 levels and PGD. Perhaps ex-
plaining this attenuation, there was a correlation between
pulmonary artery systolic pressure at induction and ICAM-
1 levels measured preoperatively (Spearman’s rho = 0.36,
p = 0.0039) and at 24 h post-reperfusion (Spearman’s rho =
0.23, p = 0.036). Furthermore, preoperative plasma ICAM-
1 levels differed according to diagnosis category (ANOVA r-
square = 0.41, p < 0.001). The lowest preoperative ICAM-1
levels were among those with COPD (mean +/− standard
deviation: 250.7 +/− 93.8), higher among CF (457.8 +/−
132.8) and IPF (429.1 +/− 194.7) and highest in congenital
heart disease (647.8 +/− 33.1). These differences in pre-
operative ICAM-1 level were independent of pulmonary
artery systolic pressure measured at induction (ANCOVA
r-square = 0.50, p < 0.001). In general, preoperative lev-
els in these conditions were higher than in the 10 normal
controls measured (mean 311.1 +/− 36.6).
Higher plasma levels of ICAM-1 were associated with an
increase in 30-day mortality (Figure 2). The mean +/− stan-
dard deviation ICAM-1 level at 24 h among those who died
was 500 +/− 187 versus 262 +/− 107 in those who sur-
vived (p < 0.0001). Among patients with PGD, higher 24-h
ICAM-1 levels appeared to confer an increased risk of 30-
day mortality, but this was inconclusive: among 26 PGD
patients, the mean ICAM-1 level was 469 +/− 191 in PGD
subjects who died (n = 5) versus 343 +/− 156 in PGD
subjects who survived (n = 21), p = 0.15.
Patients with PGD had preoperative plasma vWF levels
similar to those of patients without PGD (Figure 3). No
association between recipient clinical variables and preop-
erative vWF levels was observed. Plasma levels of vWF
increased in a linear fashion beginning 6 h postoperatively
Table 2: Bivariate and multivariable analyses of the association of
ICAM-1 levels at 24 h with PGD
Odds ratio for PGD1
(95% CI) p-Value
Unadjusted base model for
ICAM-1 level
2.12 (1.39,3.23) 0.001
ICAM-1 level adjusted for:
Recipient age 2.06 (1.33, 3.18) 0.001
Recipient gender 2.93 (1.56, 5.51) 0.001
Recipient diagnosis 1.89 (1.20, 2.98) 0.006
Recipient race/ethnicity 2.14 (1.40, 3.28) <0.001
Procedure type 2.00 (1.30, 3.10) 0.002
Cardiopulmonary bypass 1.76 (1.13, 2.75) 0.013
Use of nitric oxide 2.07 (1.35, 3.15) 0.001
Total ischemic time 2.10 (1.37, 3.23) 0.001
Pulmonary artery systolic
pressure at transplant
1.54 (0.91, 2.60) 0.109
Blood mL during first 24 h 1.92 (1.24, 3.00) 0.004
Platelet mL during first 24 h 1.94 (1.23, 3.06) 0.005
Fresh frozen plasma mL
during first 24 h
1.86 (1.16, 2.99) 0.010
1Per 100 ng/mL increase in ICAM-1 level.
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Figure 2: Plasma intercellular
adhesion molecule-1 (ICAM-1)
measured at 24 h and 30-
day mortality. Medians and in-
terquartile ranges between sub-
jects alive at 30 days and dead at
30 days are presented.
over the 72-h time period with separation of the curves be-
ginning at 24 h; however, these findings did not approach
statistical significance, except at 72 h (p = 0.054). There
were no associations of plasma vWF levels at any time
point with mortality.
Discussion
PGD results in significant morbidity and is the leading cause
of death in the first 30 days after lung transplantation
(1–4). We sought to determine whether plasma markers
Figure 3: Mean pre- and postoper-
ative plasma von Willebrand factor
antigen (vWF) concentrations over
time for lung transplant recipients
with and without primary graft dys-
function (PGD). Data are presented as
mean ± standard error.
that reflect inflammation and epithelial and endothelial in-
jury in the transplant recipient would be associated with the
development of PGD. We found that higher plasma levels
of ICAM-1 at all time points within the first 72 h after lung
transplantation were associated with PGD. In contrast, in-
creased plasma levels of vWF early after transplant were
not associated with PGD, although vWF levels did tend to
be higher in patients with PGD at 72 h after transplantation.
The expression of ICAM-1 in PGD following lung transplan-
tation has been described in animal models (18,19). During
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pulmonary reperfusion in rats transplanted with lungs do-
nated after cardiac death, an increase in ICAM-1 expres-
sion was observed in alveolar tissue (18,19). This increased
expression was attenuated by administration of ICAM-
1 anti-sense oligonucleotides instilled into the pulmonary
vasculature during the preservation period. Suppression
of ICAM-1 expression led to significant improvements in
physiological outcomes including oxygenation, pulmonary
vascular resistance, pulmonary blood flow and recipient
survival (18,19). Therefore, in addition to being a potential
biomarker of PGD, ICAM-1 might also contribute to the
pathogenesis of PGD and could represent a novel thera-
peutic target.
We found an association between plasma ICAM-1 lev-
els and pulmonary artery pressure before transplantation.
This association has also been described in sickle cell
patients with pulmonary hypertension (20). This observa-
tion is thought to be a consequence of release of ICAM-
1 from endothelial cells due to leukocyte activation and
deficits in nitric oxide production. Nitric oxide production
normally suppresses ICAM-1 expression. ICAM-1 could,
therefore, provide a mechanistic link between preoperative
pulmonary hypertension and PGD and serve to prime cir-
culating macrophages, which infiltrate the lung allograft(s).
Furthermore, preoperative plasma ICAM-1 levels were
lowest among subjects with a diagnosis of COPD. This
finding was independent of the degree of pulmonary hy-
pertension. Therefore, upregulation of ICAM-1 may also re-
flect the preoperative inflammatory states associated with
cystic fibrosis and idiopathic pneumonia syndromes, inde-
pendent of pulmonary hypertension. This notion is further
supported by the fact that plasma ICAM-1 levels were
higher in these conditions than normal controls. Alterna-
tively, higher ICAM-1 concentrations may simply be an
epiphenomenon of pulmonary hypertension, preoperative
diagnosis and acute lung injury.
Despite extremely high levels in the entire transplant co-
hort, plasma levels of vWF did not differ between the two
groups except at 72 h (p = 0.054). This finding is surprising
considering that the plasma levels of vWF in this study are
substantially higher than plasma levels in patients enrolled
in a large clinical trial of patients with ALI and acute respira-
tory distress syndrome (ARDS) (16) and are approximately
10-fold higher than levels reported in normal controls (15).
Furthermore, the lack of association of plasma vWF lev-
els with PGD contrasts with other forms of ALI and ARDS
where elevated plasma levels of vWF early in the course of
ALI and ARDS are predictive of death, prolonged mechan-
ical ventilation and organ failure (14–16). These findings
suggest that markers of endothelial damage may not be
the best predictors of graft function in the early postoper-
ative period of lung transplantation, considering the vWF
levels appeared so high across all transplant subjects. In
contrast, measures of epithelial integrity may be more re-
vealing in early PGD. Interestingly, in a small study of pa-
tients with severe PGD, the edema fluid-to-plasma protein
ratio, a measure of alveolar-capillary barrier permeability,
was also not associated with patient outcomes whereas
the rate of alveolar fluid clearance, a marker of alveolar
epithelial integrity was (21).
There are some limitations to this study. First, we chose
Grade 3 PGD as the primary outcome, which represents
the most severe form of the disease. However, recently
published studies demonstrate that Grade 3 PGD is most
predictive of morbidity and mortality in lung transplant re-
cipients (22). The levels of ICAM-1 and vWF measured in
our study in other grades of PGD (Grades 0–2) were not
significantly different (data not shown), demonstrating that
Grade 3 PGD is clearly distinct. Second, although our study
had adequate power to detect differences in biomarkers
between PGD groups, we lacked sufficient power to com-
pletely explore effects on mortality since only 6 subjects
died and, therefore, multivariable models were not pos-
sible. Future studies aimed at prediction of mortality will
need to include more patients. Third, we measured ICAM-
1 preoperatively at the time of transplantation. Thus the
utility of preoperative ICAM-1 measurement for prediction
of PGD will need to be assessed with consideration for the
hours required for the test to be performed. Similar issues
apply to the recent finding that preoperative VEGF levels
are associated with PGD (23). Future studies may need to
focus on earlier measurement to provide adequate time
to impact management. Fourth, as this is a human obser-
vational study, we are uncertain if this link represents a
causal one, or simply an epiphenomenon. The elevation
of ICAM-1 levels may simply reflect the treatments and
systemic illness that go along with severe PGD. Further
laboratory and human research will be needed both to es-
tablish causality as well as to assess clinical utility of ICAM
measurement in practice.
In a prior publication in the same cohort of subjects, we
found a similar relationship between type-1 plasminogen
activator inhibitor (PAI-1) and both pulmonary hypertension
and PGD (17). In the current study, we have used this same
resource to expand our focus to include measurement of
ICAM-1 and vWF. Thus the generalizability of our findings
to other populations may be limited.
In summary, we have shown that plasma levels of
ICAM-1 are associated with PGD in human lung trans-
plant recipients. Furthermore, preoperative ICAM-1 lev-
els correlate with pulmonary hypertension and diagno-
sis category. These findings, taken together with animal
studies, suggest that ICAM-1 might play a pathogenic
role in clinical PGD. Studies targeting ICAM-1 activity
and/or production in recipients or during organ preserva-
tion may be useful future directions toward preventing
PGD.
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